» Articles » PMID: 36899902

Low Gut Microbial Diversity Augments Estrogen-Driven Pulmonary Fibrosis in Female-Predominant Interstitial Lung Disease

Abstract

Although profibrotic cytokines, such as IL-17A and TGF-β1, have been implicated in the pathogenesis of interstitial lung disease (ILD), the interactions between gut dysbiosis, gonadotrophic hormones and molecular mediators of profibrotic cytokine expression, such as the phosphorylation of STAT3, have not been defined. Here, through chromatin immunoprecipitation sequencing (ChIP-seq) analysis of primary human CD4+ T cells, we show that regions within the STAT3 locus are significantly enriched for binding by the transcription factor estrogen receptor alpha (ERa). Using the murine model of bleomycin-induced pulmonary fibrosis, we found significantly increased regulatory T cells compared to Th17 cells in the female lung. The genetic absence of ESR1 or ovariectomy in mice significantly increased pSTAT3 and IL-17A expression in pulmonary CD4+ T cells, which was reduced after the repletion of female hormones. Remarkably, there was no significant reduction in lung fibrosis under either condition, suggesting that factors outside of ovarian hormones also contribute. An assessment of lung fibrosis among menstruating females in different rearing environments revealed that environments favoring gut dysbiosis augment fibrosis. Furthermore, hormone repletion following ovariectomy further augmented lung fibrosis, suggesting pathologic interactions between gonadal hormones and gut microbiota in relation to lung fibrosis severity. An analysis of female sarcoidosis patients revealed a significant reduction in pSTAT3 and IL-17A levels and a concomitant increase in TGF-β1 levels in CD4+ T cells compared to male sarcoidosis patients. These studies reveal that estrogen is profibrotic in females and that gut dysbiosis in menstruating females augments lung fibrosis severity, supporting a critical interaction between gonadal hormones and gut flora in lung fibrosis pathogenesis.

Citing Articles

Fine mapping-based multi-omics analysis interprets the gut-lung axis function of SGLT2 inhibitors.

Yuan F, Zhang T, Jia S, Zhao J, Wan B, Liu G Front Cell Infect Microbiol. 2024; 14:1447327.

PMID: 39318474 PMC: 11420167. DOI: 10.3389/fcimb.2024.1447327.


Geniposide ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β/Smad and p38MAPK signaling pathways.

Yin J, Wang Y, Fan S, Shang W, Zhu Y, Peng X PLoS One. 2024; 19(9):e0309833.

PMID: 39240867 PMC: 11379225. DOI: 10.1371/journal.pone.0309833.


Repurposing anti-osteoporosis drugs for autoimmune diseases: A two-sample Mendelian randomization study.

Xiang P, Yang C, Shen R, Huang X, Huang X, Cheng Q Heliyon. 2024; 10(14):e34494.

PMID: 39130432 PMC: 11315135. DOI: 10.1016/j.heliyon.2024.e34494.

References
1.
Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

2.
Chioma O, Mallott E, Chapman A, Van Amburg J, Wu H, Shah-Gandhi B . Gut microbiota modulates lung fibrosis severity following acute lung injury in mice. Commun Biol. 2022; 5(1):1401. PMC: 9772329. DOI: 10.1038/s42003-022-04357-x. View

3.
ODwyer D, Ashley S, Gurczynski S, Xia M, Wilke C, Falkowski N . Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019; 199(9):1127-1138. PMC: 6515865. DOI: 10.1164/rccm.201809-1650OC. View

4.
Fielding C, Jones G, McLoughlin R, McLeod L, Hammond V, Uceda J . Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity. 2014; 40(1):40-50. PMC: 3919204. DOI: 10.1016/j.immuni.2013.10.022. View

5.
. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by.... Am J Respir Crit Care Med. 1999; 160(2):736-55. DOI: 10.1164/ajrccm.160.2.ats4-99. View